Fax: (011) 61 2 99549418
So-called “malignant blue nevus”
A clinicopathologic study of 23 patients
Version of Record online: 26 MAY 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 13, pages 2949–2955, 1 July 2009
How to Cite
Martin, R. C. W., Murali, R., Scolyer, R. A., Fitzgerald, P., Colman, M. H. and Thompson, J. F. (2009), So-called “malignant blue nevus”. Cancer, 115: 2949–2955. doi: 10.1002/cncr.24319
- Issue online: 19 JUN 2009
- Version of Record online: 26 MAY 2009
- Manuscript Accepted: 17 NOV 2008
- Manuscript Revised: 11 NOV 2008
- Manuscript Received: 30 JUL 2008
- Cancer Institute NSW Clinical Research Fellowship Program
- Australian National Health and Medical Research Council
- Melanoma Foundation, University of Sydney
- blue nevus;
- blue nevus-like melanoma;
- cellular blue nevus;
- malignant blue nevus;
Melanomas that arise in association with or that resemble blue nevi are extremely rare and have been termed “malignant blue nevi.” The authors report on a single-institutional clinicopathologic study of “blue nevus-like melanomas” (BNLMs).
Twenty-six patients were identified with a “malignant blue nevus” over 29 years at the Sydney Melanoma Unit. Twenty-three patients were included in the current study after pathologic review. Clinical outcomes of those patients were compared with the outcomes in a matched control group of patients with melanoma (matched for age, sex, Breslow thickness, Clark level, ulceration, and anatomic site).
The median patient age was 44 years, and men comprised 65% of the patients. The tumors were distributed evenly among skin sites, and their median Breslow thickness was 5.5 mm. After a median follow-up of 36.5 months, there was no difference in survival (P = .702) between patients with BNLM and patients in the control group.
BNLMs tended to present at a more advanced stage, with thicker primary tumors, but had a metastatic pattern comparable to and was not more aggressive in behavior than other types of melanoma. The authors concluded that BNLMs should be treated in the same way as any other melanoma variants based on clinical staging and pathologic prognostic indices. Cancer 2009. © 2009 American Cancer Society.